Ergotamine Derivative

Cluster Headache

Postpartum Hemorrhage

Hypotension, Orthostatic

Migraine Disorders

Xerostomia

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-11"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">TRUDHESA (dihydroergotamine mesylate) nasal spray is a single-dose, drug-device combination product containing a dihydroergotamine mesylate drug constituent and a nasal spray device constituent. </p><p>The chemical name for dihydroergotamine mesylate is ergotaman-3', 6', 18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'- (phenylmethyl)-, (5'α)-, monomethanesulfonate. Its molecular weight is 679.78, and its molecular formula is C<span class="Sub">33</span>H<span class="Sub">37</span>N<span class="Sub">5</span>O<span class="Sub">5</span>∙CH<span class="Sub">4</span>O<span class="Sub">3</span>S.</p><p>The chemical structure is:</p><div class="Figure"><img alt="Chemical Structure" src="trudhesa-01.jpg"/><p class="MultiMediaCaption">Dihydroergotamine mesylate</p></div><p>The drug constituent is a dihydroergotamine mesylate solution. Each milliliter (mL) of solution contains dihydroergotamine mesylate 4.0 mg (equivalent to 3.43 mg dihydroergotamine), and the following inactive ingredients: caffeine (10.0 mg), carbon dioxide (q.s.), dextrose (50.0 mg), and water (q.s. to 1.0 mL). </p><p>TRUDHESA nasal spray, after assembly and priming, delivers 0.725 mg dihydroergotamine mesylate per spray. A total dose of 1.45 mg of dihydroergotamine mesylate is delivered in 2 sprays. The nasal spray device contains hydrofluoroalkane-134a (HFA) propellant.</p></section>

Trudhesa

dihydroergotamine mesylate

dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray

dihydroergotamine mesylate 0.725 MG/ACTUAT Metered Dose Nasal Spray [Trudhesa]

dihydroergotamine

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Medication Guide 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals 

Enroll in Patient Savings Program 

Patient Assistance Program

About Trudhesa 

FAQs: Acute Migraine 

Instructions For Use (Video): Acute Migraine 

Instructions For Use: Acute Migraine 